Ocrelizumab B cell depletion has no effect on HERV RNA expression in PBMC in MS patients.
RNaseq study of EBV and HERV transcription in whole blood from Multiple Sclerosis Patients prior to and 5 months after beginning therapy with the the CD20 B cell depleting monoclonal antibody Ocrelizumab